A new therapeutic approach to type II leprosy reaction

International Journal of Dermatology

Volumn 38, Issue 12, 1999, Pages 931-933

  Welsh, Oliverio ^a,b   Gómez, Minerva ^a   Mancias, Cecilia ^a   Ibarra Leal, Sara ^a   Millikan, Larry E ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOFAZIMINE; DAPSONE; MINOCYCLINE; PENTOXIFYLLINE; RIFAMPICIN; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEPROSY; MALE; RECURRENCE RISK; SKIN BIOPSY; SKIN DISCOLORATION;

ADULT; AGED; CLOFAZIMINE; DRUG THERAPY, COMBINATION; ERYTHEMA NODOSUM; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; PENTOXIFYLLINE;

EID: 0343938878     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00755.x     Document Type: Article

References (12)

1. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiol 1994; 191: 564-568.
2. Barnes PF, Chatterjee D, Brennan PJ et al. Tumor necrosis factor production in patients with leprosy. Infect Immunol 1992; 60: 1441-1446.
3. Crawford CL. Use of thalidomide in leprosy. Adverse Drug React Toxicol Rev 1994; 13: 177-192.
4. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414.
5. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982; 7: 317-323.
6. Sheskin J. Thalidomide in the treatment of lepra reactions. Lepr Rev 1965; 6: 303-306.
7. Bila V, Kren V. Evidence for teratogenicity of thalidomide using congenic and recombinant inbred rat strains. Folia Bioll Praha 1994; 40: 161-171.
8. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241-247.
9. Pearson JMH. The use of corticosteroid in lepra. Lepr Rev 1981; 52: 293-298.
10. Bienvenu J, Coulon L, Barbier Y, et al. Study of pentoxifylline induced modulation of TNF alpha and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model in whole blood. Nouv Rev Fr Hematol 1992; 34 (Suppl.): 565-567.
11. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiol 1993; 187: 447-463.
12. Goihman-Yahr M, Convit J, Rodriguez-Ochoa G, et al. Significance of neutrophil activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant disease. Int Arch Allergy Appl Immunol 1978; 57: 317-332.